Abstract | BACKGROUND AND PURPOSE: METHODS: Pretreatment with warfarin (0.2 mg/kg per day), rivaroxaban (2 mg/kg per day), apixaban (10 mg/kg per day), or vehicle (0.5% carboxymethyl cellulose sodium salt) was performed for 7 days. Transient middle cerebral artery occlusion was then induced for 120 minutes, followed by reperfusion with tissue-type plasminogen activator (10 mg/kg per 10 mL). Clinical parameters, including cerebral infarction volume, hemorrhagic volume, and blood coagulation, were examined. Twenty-four hours after reperfusion, markers for the neurovascular unit at the peri-ischemic lesion were immunohistochemically examined in brain sections, and matrix metalloproteinase-9 activity was measured by zymography. RESULTS: CONCLUSIONS:
|
Authors | Syoichiro Kono, Toru Yamashita, Kentaro Deguchi, Yoshio Omote, Taijun Yunoki, Kota Sato, Tomoko Kurata, Nozomi Hishikawa, Koji Abe |
Journal | Stroke
(Stroke)
Vol. 45
Issue 8
Pg. 2404-10
(Aug 2014)
ISSN: 1524-4628 [Electronic] United States |
PMID | 24984746
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 American Heart Association, Inc. |
Chemical References |
- Anticoagulants
- Fibrinolytic Agents
- Morpholines
- Pyrazoles
- Pyridones
- Thiophenes
- apixaban
- Rivaroxaban
- Tissue Plasminogen Activator
|
Topics |
- Animals
- Anticoagulants
(pharmacology, therapeutic use)
- Blood Coagulation
(drug effects)
- Brain
(drug effects)
- Brain Ischemia
(drug therapy)
- Fibrinolytic Agents
(adverse effects, therapeutic use)
- Intracranial Hemorrhages
(etiology, prevention & control)
- Male
- Morpholines
(pharmacology, therapeutic use)
- Pyrazoles
(pharmacology, therapeutic use)
- Pyridones
(pharmacology, therapeutic use)
- Rats
- Rats, Wistar
- Rivaroxaban
- Stroke
(drug therapy)
- Thiophenes
(pharmacology, therapeutic use)
- Thrombolytic Therapy
(adverse effects)
- Tissue Plasminogen Activator
(adverse effects, therapeutic use)
|